title: Magic bullet, part III?
abstract: In this issue of Blood, Oliveri and colleagues and Magro and colleagues report pilot trials using imatinib for steroid refractory sclerotic cGVHD,showing response rates of 79%and 50%.
authors.affiliation: Johns Hopkins University, Baltimore, MD, USA.
authors.forename: Georgia B
authors.initials: GB
authors.lastname: Vogelsang